Physician profile
Michael E Zevitz
NPI 1871543843
$1,850.15
in general payments reported to CMS, 2019-2025
20 companies · $206 in 2025
The $206 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $148 · 2021: $374 · 2022: $563 · 2023: $238 · 2024: $122 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $547 · Education: $18.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $547.05 |
| Education | $18.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $329.56 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $286.06 | 2021-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $271.96 | 2021-2022 | |
| Atricure, INC. | $205.87 | 2025 | Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| Novo Nordisk INC | $146.10 | 2020-2024 | Wegovy |
| Lilly USA, LLC | $115.02 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $108.40 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $58.28 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $49.21 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $48.11 | 2023 | Camzyos |
| Abbvie INC. | $47.15 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $33.45 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.69 | 2022 | |
| Janssen Pharmaceuticals, INC | $22.74 | 2019 | |
| Neurocrine Biosciences, INC. | $19.73 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $18.99 | 2023 | Evkeeza |
| Allergan, INC. | $18.57 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.61 | 2022 | |
| Xeris Pharmaceuticals, INC. | $14.12 | 2021 | |
| Lundbeck LLC | $11.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Zevitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.